Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call Transcript

Bajaj Healthcare Earnings Call Transcript: Key Takeaways

Bajaj Healthcare is pivoting from high-volume commodities to high-margin specialized APIs and formulations, targeting a ₹1000 Cr topline via new oncology and peptide capacities.

Guidance and delivery
Management target Revenue 15.0% FY27
Highlights
Revenue growthRevenue rose 11.3% YoY to ₹165.6 Cr, primarily volume-led.
MarginsEBITDA margins improved 70 bps YoY to 17.8%.
Demand visibilityStrong demand in domestic API and upcoming specialized oncology/peptide segments.
Management confidenceConfident, focusing on transitioning to high-value science-led API modules.

Growth

Revenue grew 11.3% YoY to ₹165.6 Cr, driven by a 27% surge in domestic API volumes.

Outlook

Management guides for 10-15% topline and profit growth in FY27, aiming for ₹1000 Cr revenue by FY29.

Risks

Prolonged high working capital cycles and inventory bunching due to geopolitical risk remain key concerns.

Source

Earnings Call Transcript filed with NSE, NSE: BAJAJHCARE. Summary written with AI assistance from the document.

Read the document ↗

Bajaj Healthcare Ltd: key numbers

Share price
₹344.15
Market cap
₹1,159 Cr
Revenue (annual)
₹611.0 Cr
Net profit (annual)
₹15.77 Cr
P/E (TTM)
65.7×Sector 50.4×
Promoter holding
58.59%+0.30% QoQ
FII holding
2.19%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Bajaj Healthcare Ltd

All →
17:33 IST BSE
Annual General Meeting

Bajaj Healthcare Annual General Meeting

Bajaj Healthcare Limited concluded its 33rd Annual General Meeting on September 21, 2026. The shareholders transacted ordinary and special business, including a final dividend declaration.

11:36 IST BSE
Dividend

Bajaj Healthcare Dividend

Bajaj Healthcare Limited has fixed September 14, 2026, as the record date for a 30% final dividend. The dividend of ₹1.50 per share awaits shareholder approval.